Abstract
Our article on complex buffering antacids concluded that magaldrate should not have been added to the DHSS limited list on the assumption that a drug would be added only if it had an advantage over those already listed in terms of safety, efficacy, cost or convenience. However, the terms of reference of the Advisory Committee on NHS Drugs which were subsequently published state that a drug will be included if there is “objective evidence that there is a real clinical need for the product which is not met by drugs already available under the NHS or is as effective as the available drugs at the same cost or less”. The last phrase fully justifies the re-introduction of magaldrate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
